Your browser doesn't support javascript.
loading
A Randomized Controlled Clinical Trial of Nasal Immunization with Live Virulence Attenuated Streptococcus pneumoniae Strains Using Human Infection Challenge.
Hill, Helen; Mitsi, Elena; Nikolaou, Elissavet; Blizard, Annie; Pojar, Sherin; Howard, Ashleigh; Hyder-Wright, Angela; Devin, Jack; Reiné, Jesus; Robinson, Ryan; Solórzano, Carla; Jochems, Simon P; Kenny-Nyazika, Tinashe; Ramos-Sevillano, Elisa; Weight, Caroline M; Myerscough, Chris; McLenaghan, Daniella; Morton, Ben; Gibbons, Emily; Farrar, Madlen; Randles, Victoria; Burhan, Hassan; Chen, Tao; Shandling, Adam D; Campo, Joe J; Heyderman, Robert S; Gordon, Stephen B; Brown, Jeremy S; Collins, Andrea M; Ferreira, Daniela M.
Afiliación
  • Hill H; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Mitsi E; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Nikolaou E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Blizard A; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Pojar S; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Howard A; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Hyder-Wright A; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Devin J; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Reiné J; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
  • Robinson R; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Solórzano C; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Jochems SP; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • Kenny-Nyazika T; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Ramos-Sevillano E; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
  • Weight CM; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Myerscough C; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
  • McLenaghan D; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Morton B; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Gibbons E; UCL Respiratory, Division of Medicine, University College London, London, United Kingdom.
  • Farrar M; Division of Infection and Immunity, University College London, London, United Kingdom.
  • Randles V; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Burhan H; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Chen T; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Shandling AD; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Campo JJ; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Heyderman RS; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Gordon SB; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
  • Brown JS; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
  • Collins AM; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Ferreira DM; Antigen Discovery Inc, Irvine, California; and.
Am J Respir Crit Care Med ; 208(8): 868-878, 2023 Oct 15.
Article en En | MEDLINE | ID: mdl-37556679
Rationale: Pneumococcal pneumonia remains a global health problem. Pneumococcal colonization increases local and systemic protective immunity, suggesting that nasal administration of live attenuated Streptococcus pneumoniae (Spn) strains could help prevent infections. Objectives: We used a controlled human infection model to investigate whether nasopharyngeal colonization with attenuated S. pneumoniae strains protected against recolonization with wild-type (WT) Spn (SpnWT). Methods: Healthy adults aged 18-50 years were randomized (1:1:1:1) for nasal administration twice (at a 2-wk interval) with saline solution, WT Spn6B (BHN418), or one of two genetically modified Spn6B strains, SpnA1 (Δfhs/piaA) or SpnA3 (ΔproABC/piaA) (Stage I). After 6 months, participants were challenged with SpnWT to assess protection against the homologous serotype (Stage II). Measurements and Main Results: 125 participants completed both study stages per intention to treat. No serious adverse events were reported. In Stage I, colonization rates were similar among groups: SpnWT, 58.1% (18 of 31); SpnA1, 60% (18 of 30); and SpnA3, 59.4% (19 of 32). Anti-Spn nasal IgG levels after colonization were similar in all groups, whereas serum IgG responses were higher in the SpnWT and SpnA1 groups than in the SpnA3 group. In colonized individuals, increases in IgG responses were identified against 197 Spn protein antigens and serotype 6 capsular polysaccharide using a pangenome array. Participants given SpnWT or SpnA1 in Stage I were partially protected against homologous challenge with SpnWT (29% and 30% recolonization rates, respectively) at stage II, whereas those exposed to SpnA3 achieved a recolonization rate similar to that in the control group (50% vs. 47%, respectively). Conclusions: Nasal colonization with genetically modified live attenuated Spn was safe and induced protection against recolonization, suggesting that nasal administration of live attenuated Spn could be an effective strategy for preventing pneumococcal infections. Clinical trial registered with the ISRCTN registry (ISRCTN22467293).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Streptococcus pneumoniae Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Neumocócicas / Streptococcus pneumoniae Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos